gsk2816126
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 24, 2014 (NCT02082977)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
EZH2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@H](C)n1cc(C)c2c(C(=O)NCc3c(C)cc(C)[nH]c3=O)cc(-c3ccc(N4CCNCC4)nc3)cc21- Mol. weight
- 526.69 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3287735 ↗
Also known as
- gsk2816126
- gsk2816126
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02082977 | Phase 1 | Apr 24, 2014 | GlaxoSmithKline |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2014 |
1 organizations
Page 1 / 1